Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GKOS
GLAUKOS CORPORATION
NYSE
$179.87
▼ DOWN 1.12% (-2.04)

KEY STATISTICS

Market Cap$10.61 B
52w High$191.62
52w Low$73.16
Dividend Yield—
Frequency—
P/E-209.15
Volume551.89K
Shares Out.58.98M

COMPANY

LEADERSHIP

Thomas William Burns
CHIEF EXECUTIVE
Thomas William Burns

COMPENSATION 2026

Salary$800,000
Stock Awards$6,395,008
Incentive Plan Pay$0
All Other Comp.$10,350
Total$9,030,345

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 25, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
1,094

PRICE TARGET

Target High$215.00
Target Low$150.00
Target Median$195.00
Target Consensus$190.75

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$167.93M
NOV
4
WED

PRICE

$179.87 ▼ DOWN 1.12% (−$2.04)
$179$180$1829:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM179.87

About Glaukos Corporation

https://www.glaukos.com ↗

Glaukos Corporation develops innovative ophthalmic therapies, including micro-bypass stents and drug delivery implants, for glaucoma, corneal, and retinal diseases, serving global markets from its California headquarters.

INDUSTRY

Medical - Devices

A PRODUCT GLAUKOS CORPORATION IS KNOWN FOR

iDose TR
iDose TR

An FDA-approved implant that continuously delivers travoprost to lower intraocular pressure in glaucoma or ocular hypertension patients, offering a long-lasting, innovative solution to improve compliance over traditional eye drops.

COMPETITORS

COMPETITOR
ABBV COMPARE
ALC COMPARE
EYPT COMPARE
OCUL COMPARE
SGHT COMPARE

Revenue by Products

IconPRODUCTQ1-2020Q2-2020Q3-2020Q4-2020
Glaucoma$44.13M $24.95M ▼$51.93M ▲$58.36M ▲
Corneal Health$11.2M $6.61M ▼$12.9M ▲$14.88M ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$101.45M $108M ▲$112.34M ▲$146.74M ▲
NonUS$32.09M $35.12M ▲$38.23M ▲$38.87M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
201
LISTED HERE
26
RANKED BY POSITION SIZE
XSMH.TO
0.58% · 3.6M
VTI
0.01% · 1.8M
SPSM
0.59% · 553.5K
SCHA
0.22% · 279.1K
FESM
0.62% · 223.7K
PSCH
5.36% · 55.0K
XRS2.F
0.33% · 52.3K
JMEE
0.30% · 48.4K
NBDS
4.07% · 42.0K
NUSC
0.50% · 39.9K
DOCT.L
1.84% · 33.3K
FNX
0.38% · 29.5K
RSSL
0.33% · 27.5K
GSC
1.77% · 27.5K
JHMM
0.06% · 21.8K
WSCSRI.SW
0.37% · 17.1K
FFTY
3.02% · 12.6K
DFAS
0.01% · 10.5K
BKMC
0.26% · 9.4K
HTEC
1.85% · 7.9K
ZSML.TO
0.59% · 5.8K
ETHO
0.48% · 5.3K
ISMD
0.26% · 4.9K
URTY
0.13% · 2.3K
TILT
0.02% · 2.1K
OASC
0.51% · 1.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
79.64%
HOLDERS
523
TOP 12 OF 523 · RANKED BY POSITION SIZE
Blackrock, Inc.
9.5M sh · $1.33B
Blackrock Inc.
8.0M sh · $951.27M
Vanguard Group Inc
6.0M sh · $493.09M
Janus Henderson Group Plc
5.3M sh · $575.84M
Wellington Management Group Llp
3.6M sh · $292M
Primecap Management Co/Ca/
3.4M sh · $381.29M
State Street Corp
2.3M sh · $323.67M
Ameriprise Financial Inc
2.1M sh · $237.6M
Janus Henderson Investors Us LLC
1.8M sh · $90.55M
Alliancebernstein L.P.
1.7M sh · $141.36M
Millennium Management LLC
1.6M sh · $181.75M
Holocene Advisors, LP
1.5M sh · $211.73M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
Kliman Gilbert H
Purchase · 2.5K shares
2026-08-19
★
DIRECTOR
Kliman Gilbert H
Sale · 2.5K shares
2026-08-19
★
OFFICER: PRESIDENT & COO
Gilliam Joseph E
Sale · 32.0K shares
2026-08-11
★
OFFICER: PRESIDENT & COO
Gilliam Joseph E
Sale · 28.0K shares
2026-08-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OVERWEIGHT 4
NEUTRAL 1
11 GRADES IN THE LAST 12 MONTHS
BTIG BUY Citigroup BUY HC Wainwright & Co. BUY Wells Fargo OVERWEIGHT Piper Sandler OVERWEIGHT Stifel BUY Truist Securities BUY UBS NEUTRAL

SECTORS PEERS

PEERPRICE
ARWR$84.91COMPARE
BRKR$57.08COMPARE
ALKS$47.41COMPARE
OSCR$30.47COMPARE
TFX$139.67COMPARE
BLCO$17.15COMPARE
MMSI$90.49COMPARE
IRTC$120.25COMPARE